Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
- PMID: 30420618
- PMCID: PMC6288087
- DOI: 10.1038/s41416-018-0302-8
Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
Abstract
Background: The evaluation of the proportional hazards (PH) assumption in survival analysis is an important issue when Hazard Ratio (HR) is chosen as summary measure. The aim is to assess the appropriateness of statistical methods based on the PH assumption in oncological trials.
Methods: We selected 58 randomised controlled trials comparing at least two pharmacological treatments with a time-to-event as primary endpoint in advanced non-small-cell lung cancer. Data from Kaplan-Meier curves were used to calculate the relative hazard at each time point and the Restricted Mean Survival Time (RMST). The PH assumption was assessed with a fixed-effect meta-regression.
Results: In 19% of the trials, there was evidence of non-PH. Comparison of treatments with different mechanisms of action was associated (P = 0.006) with violation of the PH assumption. In all the superiority trials where non-PH was detected, the conclusions using the RMST corresponded to that based on the Cox model, although the magnitude of the effect given by the HR was systematically greater than the one from the RMST ratio.
Conclusion: As drugs with new mechanisms of action are being increasingly employed, particular attention should be paid on the statistical methods used to compare different types of agents.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.Pharm Stat. 2018 May;17(3):202-213. doi: 10.1002/pst.1846. Epub 2017 Dec 28. Pharm Stat. 2018. PMID: 29282880
-
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797. JAMA Oncol. 2017. PMID: 28975263 Free PMC article.
-
[Application of restricted mean survival time in clinical follow-up study].Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Feb 10;40(2):247-250. doi: 10.3760/cma.j.issn.0254-6450.2019.02.023. Zhonghua Liu Xing Bing Xue Za Zhi. 2019. PMID: 30744281 Chinese.
-
Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.J Clin Oncol. 2016 May 20;34(15):1813-9. doi: 10.1200/JCO.2015.64.2488. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884584 Review.
-
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.Semin Oncol. 2018 Aug;45(4):220-225. doi: 10.1053/j.seminoncol.2018.08.007. Epub 2018 Oct 31. Semin Oncol. 2018. PMID: 30391014 Review.
Cited by
-
Prognostic Factors of Survival of Advanced Liver Cancer Patients Treated With Palliative Radiotherapy: A Retrospective Study.Front Oncol. 2021 Jul 28;11:658152. doi: 10.3389/fonc.2021.658152. eCollection 2021. Front Oncol. 2021. PMID: 34395242 Free PMC article.
-
Environmental exposures associated with early childhood recurrent wheezing in the mother and child in the environment birth cohort: a time-to-event study.Thorax. 2024 Sep 18;79(10):953-960. doi: 10.1136/thorax-2023-221150. Thorax. 2024. PMID: 38964859 Free PMC article.
-
A systematic review of the quality of conduct and reporting of survival analyses of tuberculosis outcomes in Africa.BMC Med Res Methodol. 2021 Apr 27;21(1):89. doi: 10.1186/s12874-021-01280-3. BMC Med Res Methodol. 2021. PMID: 33906605 Free PMC article.
-
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.Clin Cancer Res. 2024 Oct 15;30(20):4791-4799. doi: 10.1158/1078-0432.CCR-24-0566. Clin Cancer Res. 2024. PMID: 39133081 Free PMC article.
-
Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China.Breast. 2025 Aug 5;83:104550. doi: 10.1016/j.breast.2025.104550. Online ahead of print. Breast. 2025. PMID: 40768820 Free PMC article.
References
-
- Kaplan EMP. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958;53:457–481. doi: 10.1080/01621459.1958.10501452. - DOI
-
- Cox D. Regression models and life-tables. J. Royal Stat. Soc. Ser B (Method) 1972;34:187–220.
-
- Breslow N. Analysis of survival data under the proportional hazards model. Int. Stat. Rev. 1975;43:45–57. doi: 10.2307/1402659. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials